Related Experiment Video
Updated: May 10, 2026
Therapeutic Gene Delivery and Transfection in Human Pancreatic Cancer Cells using Epidermal Growth Factor Receptor-targeted Gelatin Nanoparticles
Published on: January 4, 2012
EGRF conjugated PEGylated nanographene oxide for targeted chemotherapy and photothermal therapy
Hung-Wei Yang1, Yu-Jen Lu, Kun-Ju Lin
1Department of Chemical Engineering, National Tsing Hua University, 101, Section 2, Kuang-Fu Road, Hsin-chu 30013, Taiwan, ROC.
Abstract:
Low accumulation of chemotherapeutic agent in tumor tissue and multidrug resistance (MDR) present a major obstacle to curing cancer treatment. Therefore, how to combine several therapeutics in one system is a key issue to overcome the problem. Here, we demonstrate epidermal growth factor receptor (EGFR) antibody-conjugated PEGylated nanographene oxide (PEG-NGO) to carry epirubicin (EPI) for tumor targeting and triple-therapeutics (growth signal blocking, chemotherapy, photothermal therapy) in tumor treatment. This synergistic targeted treatment simultaneously enhances the local drug concentration (6.3-fold) and performs the ultra-efficient tumor suppression to significantly prolong the mice survival (over the course of 50 days).
Insights
This study developed a targeted nanographene oxide system for cancer treatment, combining chemotherapy and photothermal therapy. The novel approach significantly improved drug delivery and suppressed tumor growth in mice.
Area of Science:
- Biomedical Engineering
- Nanotechnology
- Oncology
Background:
- Multidrug resistance (MDR) and insufficient chemotherapeutic agent accumulation in tumor tissues hinder effective cancer treatment.
- Developing multifunctional therapeutic systems is crucial for overcoming these challenges.
Purpose of the Study:
- To create a targeted nanographene oxide (NGO) system for enhanced cancer therapy.
- To investigate the synergistic effects of chemotherapy, photothermal therapy, and growth signal blocking.
Main Methods:
- Conjugating epidermal growth factor receptor (EGFR) antibody to PEGylated nanographene oxide (PEG-NGO).
- Loading epirubicin (EPI) onto the PEG-NGO-EGFR system for targeted drug delivery.
- Evaluating the triple-therapeutic approach (chemotherapy, photothermal therapy, growth signal blocking) in a tumor model.
Main Results:
- The developed system significantly enhanced local drug concentration by 6.3-fold.
- Achieved ultra-efficient tumor suppression, prolonging mouse survival beyond 50 days.
- Demonstrated successful tumor targeting and synergistic therapeutic effects.
Conclusions:
- EGFR antibody-conjugated PEG-NGO carrying epirubicin offers a promising strategy for synergistic, targeted cancer treatment.
- This approach effectively overcomes MDR and low drug accumulation, improving therapeutic outcomes.
- The combination of chemotherapy, photothermal therapy, and growth signal blocking shows significant potential in preclinical cancer models.
